| # | Drug | Count |
|---|---|---|
| 0 | ADALIMUMAB | 161 |
| 1 | METHOTREXATE SODIUM | 145 |
| 2 | METHOTREXATE | 126 |
| 3 | PREDNISONE | 107 |
| 4 | ETANERCEPT | 106 |
| 5 | INFLIXIMAB | 72 |
| 6 | ADALIMUMAB-AATY | 60 |
| 7 | ADALIMUMAB-ADAZ | 60 |
| 8 | ADALIMUMAB-FKJP | 60 |
| 9 | PEMBROLIZUMAB | 50 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | BEVACIZUMAB-ADCD | 5 | 0.0246 |
| 1 | CHLORPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HCL | 1 | 0.0040 |
| 2 | ERGOTAMINE TARTRATE AND CAFFEINE | 1 | 0.0037 |
| 3 | INFLIXIMAB-DYYB | 11 | 0.0032 |
| 4 | REPOSITORY CORTICOTROPIN | 14 | 0.0031 |
| 5 | SUTIMLIMAB-JOME | 1 | 0.0031 |
| 6 | CARBAMIDE PEROXIDE | 1 | 0.0023 |
| 7 | HYALURONATE SODIUM | 3 | 0.0020 |
| 8 | NELFINAVIR MESYLATE | 4 | 0.0019 |
| 9 | METHYLCELLULOSE | 4 | 0.0017 |
| # | Drug class | Count |
|---|---|---|
| 0 | Tumor Necrosis Factor Blocker [EPC] | 258 |
| 1 | Corticosteroid [EPC] | 175 |
| 2 | Folate Analog Metabolic Inhibitor [EPC] | 133 |
| 3 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 89 |
| 4 | Nonsteroidal Anti-inflammatory Drug [EPC] | 70 |
| 5 | Platinum-based Drug [EPC] | 51 |
| 6 | Proton Pump Inhibitor [EPC] | 51 |
| 7 | Interferon beta [EPC] | 49 |
| 8 | Vitamin C [EPC] | 45 |
| 9 | CD20-directed Cytolytic Antibody [EPC] | 43 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Adrenocorticotropic Hormone [EPC] | 14 | 0.0156 |
| 1 | Interleukin-5 Antagonist [EPC] | 9 | 0.0131 |
| 2 | Classical Complement Pathway Inhibitor [EPC] | 1 | 0.0031 |
| 3 | Provitamin D2 Compound [EPC] | 30 | 0.0010 |
| 4 | Actinomycin [EPC] | 2 | 0.0009 |
| 5 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 89 | 0.0009 |
| 6 | Interleukin-17A Antagonist [EPC] | 25 | 0.0007 |
| 7 | CTLA-4-directed Blocking Antibody [EPC] | 24 | 0.0005 |
| 8 | Interleukin-17 Receptor A Antagonist [EPC] | 1 | 0.0005 |
| 9 | Guanylate Cyclase-C Agonist [EPC] | 1 | 0.0005 |